AEON Biopharma, Inc. (AEON): auditor change — AEON Biopharma dismisses EY as auditor, engages KPMG, effective Sep 28, 2023

AEON Biopharma, Inc.

Audit Committee dismissed EY on Sep 28, 2023; EY's prior reports included a going-concern qualification.
No disagreements with EY on accounting principles or audit scope during 2021-2022 or interim period.
Board approved engagement of KPMG as independent auditor for fiscal year ending Dec 31, 2023.
Neither the Company nor anyone on its behalf consulted KPMG on accounting matters prior to engagement.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

AEON Biopharma, Inc. dismissed Ernst & Young LLP as its auditor.

Action: dismissal
Auditor: Ernst & Young LLP
Successor: KPMG LLP

Exact text from the filing

On September 28, 2023 (the "Dismissal Date"), the Audit Committee of the Board of Directors of AEON Biopharma, Inc. (the "Company") approved the dismissal of Ernst & Young LLP ("EY") as the independent registered public accounting firm for AEON Biopharma Sub, Inc., (the "Operating Company"), effective immediately.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

AEON Biopharma, Inc. engaged KPMG LLP as its auditor.

Action: engagement
Auditor: KPMG LLP

Exact text from the filing

On September 28, 2023, the Audit Committee recommended, and the Board of Directors of the Company approved, the engagement of KPMG LLP ("KPMG") as the Company's new independent registered public accounting firm for the Company's fiscal year ending December 31, 2023.

View on SEC.gov

6 auditor changes filed in the last 30 days. Browse all auditor changes →

AEON Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-105964

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.